Brian Durkin Net Worth

The estimated Net Worth of Brian L Durkin is at least $8.06 Milhão dollars as of 9 March 2022. Mr. Durkin owns over 18,628 units of Abbvie Inc stock worth over $3,715,501 and over the last 6 years he sold ABBV stock worth over $4,347,372. In addition, he makes $0 as Vice President e Controller at Abbvie Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Durkin ABBV stock SEC Form 4 insiders trading

Brian has made over 4 trades of the Abbvie Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 18,628 units of ABBV stock worth $2,794,386 on 9 March 2022.

The largest trade he's ever made was selling 18,628 units of Abbvie Inc stock on 9 March 2022 worth over $2,794,386. On average, Brian trades about 2,165 units every 68 days since 2019. As of 9 March 2022 he still owns at least 19,094 units of Abbvie Inc stock.

You can see the complete history of Mr. Durkin stock trades at the bottom of the page.

Brian Durkin biography

Brian L. Durkin serves as Vice President, Controller of the Company. Mr. Durkin previously served as Vice President, Internal Audit from 2016 to 2018. Prior to joining AbbVie, he served as Vice President of Finance and Division Controller for Abbott’s Vision Care business from 2009 to 2016 and Controller Pharmaceutical Research and Development from 2005 to 2009. Mr. Durkin joined Abbott in 1986.

How old is Brian Durkin?

Brian Durkin is 58, he's been the Vice President e Controller of Abbvie Inc since 2018. There are 13 older and 17 younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.

What's Brian Durkin's mailing address?

Brian's mailing address filed with the SEC is North Waukegan Road, North Chicago, Lake County, Illinois, 60044, United States.

Insiders trading at Abbvie Inc

Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell, eGlenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.

What does Abbvie Inc do?

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Complete history of Mr. Durkin stock trades at Abbvie Inc

Abbvie Inc executives and stock owners

Abbvie Inc executives and other stock owners filed with the SEC include:

• Richard Gonzalez,
  Chairman of the Board, Chief Executive Officer
• Laura Schumacher,
  Vice Chairman, External Affairs and Chief Legal Officer
• Carlos Alban,
  Vice Chairman, Chief Commercial Officer
• Michael Severino,
  President, Vice Chairman
• Robert Michael,
  Chief Financial Officer, Senior Vice President
• William Chase,
  Executive Vice President - Finance and Administration
• Richard A. Gonzalez,
  Chairman & CEO
• Dr. Michael E. Severino,
  Vice Chairman & Pres
• Laura J. Schumacher,
  Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.
• Timothy Richmond,
  Chief Human Resource Officer, Executive Vice President
• Robert A. Michael,
  Vice Chairman of Fin. & Commercial Operations and CFO
• Glenn Tilton,
  Lead Independent Director
• Robert Alpern,
  Independent Director
• Edward Rapp,
  Independent Director
• Brett Hart,
  Independent Director
• William Burnside,
  Independent Director
• Roxanne Austin,
  Independent Director
• Frederick Waddell,
  Independent Director
• Melody Meyer,
  Independent Director
• Edward Liddy,
  Independent Director
• Thomas Freyman,
  Independent Director
• Rebecca Roberts,
  Independent Director
• Brian Durkin,
  Vice President, Controller
• Jeffrey Stewart,
  Senior Vice President, U.S. Commercial Operations
• Nicholas Donoghoe,
  Senior Vice President - Enterprise Innovation
• Azita Saleki-Gerhardt,
  Executive Vice President - Operations
• Henry Gosebruch,
  Executive Vice President, Chief Strategy Officer
• Scott T. Reents,
  Sr. VP & CFO
• Jeffrey Ryan Stewart,
  Exec. VP & Chief Commercial Officer
• Henry O. Gosebruch,
  Exec. VP & Chief Strategy Officer
• Scott C. Brun M.D.,
  VP of Scientific Affairs & Head of AbbVie Ventures
• Timothy J. Richmond,
  Exec. VP & Chief HR Officer
• Elizabeth Shea,
  VP of Investor Relations
• Dr. Thomas J. Hudson,
  Sr. VP of R&D and Chief Scientific Officer
• Dr. Azita Saleki-Gerhardt,
  Exec. VP of Operations
• Thomas A. Hurwich,
  VP, Controller
• Jennifer L. Davis,
  
• Roy S Roberts,
  Director
• Laboratories Abbott,
  10% owner
• John M Leonard,
  SVP, Chief Scientific Officer
• Elaine K. Sorg,
  SVP, US COMMERCIAL OPERATIONS
• Perry C Siatis,
  EVP, GC AND SECRETARY
• Carrie C Strom,
  SVP & PRES GLOBAL ALLERG AESTH
• Thomas J Hudson,
  SVP, CSO, GLOBAL RESEARCH
• Scott T Reents,
  EVP, CHIEF FINANCIAL OFFICER
• Susan E Quaggin,
  
• Kevin K Buckbee,
  SVP, CONTROLLER
• Roopal Thakkar,
  SVP, CMO, GLOBAL THERAPEUTICS